Comments

Apellis Pharmaceuticals

APLSNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$36.63
-1.35-3.55%
Last update: 12:47 PM
15 minutes delayed
Q2 2024 Earnings in 10 days from now on Thu Aug 1st, before the market open
Apellis Pharmaceuticals (APLS) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$141.00
Lowest Price Target1
$40.00
Consensus Price Target1
$75.20

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Apellis Pharmaceuticals (NASDAQ:APLS) Stock, Analyst Ratings, Price Targets, Forecasts

Apellis Pharmaceuticals Inc has a consensus price target of $75.2 based on the ratings of 20 analysts. The high is $141 issued by Goldman Sachs on April 14, 2023. The low is $40 issued by Jefferies on November 10, 2022. The 3 most-recent analyst ratings were released by Goldman Sachs, Baird, and Piper Sandler on July 17, 2024, June 28, 2024, and May 31, 2024, respectively. With an average price target of $74.33 between Goldman Sachs, Baird, and Piper Sandler, there's an implied 102.93% upside for Apellis Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
1
Mar
2
Apr
2
May
1
Jun
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.6
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Goldman Sachs
Baird
Piper Sandler
HC Wainwright & Co.
Wells Fargo

1calculated from analyst ratings

Analyst Ratings for Apellis Pharmaceuticals

Buy NowGet Alert
07/17/2024Buy Now110.21%Goldman Sachs
Salveen Richter
$90 → $77MaintainsBuyGet Alert
06/28/2024Buy Now173%Baird
Colleen Kusy
$100 → $100MaintainsOutperformGet Alert
05/31/2024Buy Now25.58%Piper Sandler
Biren Amin
 → $46Initiates → NeutralGet Alert
05/28/2024Buy Now151.16%HC Wainwright & Co.
Douglas Tsao
$92 → $92ReiteratesBuy → BuyGet Alert
05/23/2024Buy Now31.04%Wells Fargo
Derek Archila
$57 → $48MaintainsEqual-WeightGet Alert
05/08/2024Buy Now132.05%Needham
Joseph Stringer
 → $85ReiteratesBuy → BuyGet Alert
05/08/2024Buy Now63.8%Citigroup
Yigal Nochomovitz
$67 → $60MaintainsBuyGet Alert
05/08/2024Buy Now151.16%HC Wainwright & Co.
Douglas Tsao
 → $92ReiteratesBuy → BuyGet Alert
05/08/2024Buy Now132.05%UBS
Eliana Merle
$89 → $85MaintainsBuyGet Alert
04/29/2024Buy Now41.96%Mizuho
Graig Suvannavejh
$60 → $52MaintainsNeutralGet Alert
04/26/2024Buy Now151.16%HC Wainwright & Co.
Douglas Tsao
 → $92ReiteratesBuy → BuyGet Alert
04/25/2024Buy Now132.05%Needham
Joseph Stringer
 → $85ReiteratesBuy → BuyGet Alert
04/17/2024Buy Now55.61%Wedbush
Laura Chico
$67 → $57MaintainsNeutralGet Alert
04/15/2024Buy Now151.16%HC Wainwright & Co.
Douglas Tsao
 → $92ReiteratesBuy → BuyGet Alert
04/09/2024Buy Now132.05%Needham
Joseph Stringer
 → $85ReiteratesBuy → BuyGet Alert
03/27/2024Buy Now63.8%Mizuho
Graig Suvannavejh
$60 → $60MaintainsNeutralGet Alert
03/06/2024Buy Now115.67%JP Morgan
Anupam Rama
$78 → $79MaintainsOverweightGet Alert
03/04/2024Buy Now142.97%UBS
Eliana Merle
$87 → $89MaintainsBuyGet Alert
02/28/2024Buy Now151.16%HC Wainwright & Co.
Douglas Tsao
 → $92ReiteratesBuy → BuyGet Alert
02/28/2024Buy Now82.91%Wedbush
Laura Chico
$60 → $67MaintainsNeutralGet Alert
02/16/2024Buy Now63.8%Mizuho
Graig Suvannavejh
$49 → $60MaintainsNeutralGet Alert
02/06/2024Buy Now121.13%Baird
Colleen Kusy
 → $81ReiteratesOutperform → OutperformGet Alert
02/05/2024Buy Now118.4%Jefferies
Akash Tewari
$68 → $80UpgradeHold → BuyGet Alert
01/30/2024Buy Now115.67%Oppenheimer
Justin Kim
$75 → $79MaintainsOutperformGet Alert
01/24/2024Buy Now104.75%Needham
Joseph Stringer
$70 → $75MaintainsBuyGet Alert
01/17/2024Buy Now121.13%Baird
Colleen Kusy
$71 → $81MaintainsOutperformGet Alert
01/17/2024Buy Now151.16%HC Wainwright & Co.
Douglas Tsao
$82 → $92MaintainsBuyGet Alert
01/12/2024Buy Now63.8%Wedbush
Laura Chico
$39 → $60MaintainsNeutralGet Alert
01/11/2024Buy Now189.38%Raymond James
Steven Seedhouse
$67 → $106MaintainsStrong BuyGet Alert
01/09/2024Buy Now145.7%Goldman Sachs
Salveen Richter
$65 → $90MaintainsBuyGet Alert
12/15/2023Buy Now82.91%Citigroup
Yigal Nochomovitz
$70 → $67MaintainsBuyGet Alert
12/15/2023Buy Now104.75%Oppenheimer
Justin Kim
$88 → $75MaintainsOutperformGet Alert
12/15/2023Buy Now82.91%Raymond James
Steven Seedhouse
$93 → $67MaintainsStrong BuyGet Alert
12/14/2023Buy Now52.88%Needham
Joseph Stringer
$63 → $56MaintainsBuyGet Alert
12/14/2023Buy Now47.42%Wells Fargo
Derek Archila
$67 → $54DowngradeOverweight → Equal-WeightGet Alert
12/05/2023Buy Now132.05%B of A Securities
Tazeen Ahmad
$52 → $85UpgradeNeutral → BuyGet Alert
11/09/2023Buy Now102.02%Goldman Sachs
Salveen Richter
 → $74Initiates → BuyGet Alert
11/02/2023Buy Now14.66%Mizuho
Graig Suvannavejh
 → $42Initiates → NeutralGet Alert
11/02/2023Buy Now153.89%Raymond James
Steven Seedhouse
$92 → $93MaintainsStrong BuyGet Alert
11/01/2023Buy Now71.99%Needham
Joseph Stringer
$60 → $63MaintainsBuyGet Alert
10/12/2023Buy Now25.58%B of A Securities
Brian Cheng
$44 → $46MaintainsNeutralGet Alert
10/06/2023Buy Now91.1%Citigroup
Yigal Nochomovitz
$54 → $70MaintainsBuyGet Alert
10/06/2023Buy Now121.13%JP Morgan
Anupam Rama
$60 → $81UpgradeNeutral → OverweightGet Alert
10/06/2023Buy Now151.16%Raymond James
Steven Seedhouse
$89 → $92MaintainsStrong BuyGet Alert
09/26/2023Buy Now123.86%HC Wainwright & Co.
Douglas Tsao
 → $82ReiteratesBuy → BuyGet Alert
09/20/2023Buy Now123.86%HC Wainwright & Co.
Douglas Tsao
 → $82ReiteratesBuy → BuyGet Alert
09/15/2023Buy Now74.72%Wells Fargo
Derek Archila
$34 → $64UpgradeEqual-Weight → OverweightGet Alert
09/14/2023Buy Now123.86%HC Wainwright & Co.
Douglas Tsao
 → $82ReiteratesBuy → BuyGet Alert
09/08/2023Buy Now17.39%B of A Securities
Brian Cheng
$40 → $43MaintainsNeutralGet Alert
08/30/2023Buy Now47.42%Citigroup
Yigal Nochomovitz
$45 → $54MaintainsBuyGet Alert
08/30/2023Buy Now63.8%Needham
Joseph Stringer
 → $60ReiteratesBuy → BuyGet Alert
08/29/2023Buy Now77.45%Stifel
Annabel Samimy
$60 → $65MaintainsBuyGet Alert
08/24/2023Buy Now63.8%Needham
Joseph Stringer
 → $60ReiteratesBuy → BuyGet Alert
08/23/2023Buy Now—Oppenheimer
Justin Kim
—ReiteratesOutperform → OutperformGet Alert
08/23/2023Buy Now-20.83%Wedbush
Laura Chico
 → $29ReiteratesNeutral → NeutralGet Alert
08/23/2023Buy Now74.72%UBS
Eliana Merle
$60 → $64MaintainsBuyGet Alert
08/23/2023Buy Now123.86%HC Wainwright & Co.
Douglas Tsao
 → $82ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now-20.83%Wedbush
Laura Chico
$32 → $29MaintainsNeutralGet Alert
08/07/2023Buy Now123.86%HC Wainwright & Co.
Douglas Tsao
 → $82ReiteratesBuy → BuyGet Alert
08/03/2023Buy Now63.8%JP Morgan
Anupam Rama
$72 → $60DowngradeOverweight → NeutralGet Alert
08/01/2023Buy Now91.1%Baird
Colleen Kusy
$115 → $70MaintainsOutperformGet Alert
08/01/2023Buy Now9.2%B of A Securities
Brian Cheng
$114 → $40DowngradeBuy → NeutralGet Alert
08/01/2023Buy Now123.86%HC Wainwright & Co.
Douglas Tsao
 → $82ReiteratesBuy → BuyGet Alert
08/01/2023Buy Now142.97%Raymond James
Steven Seedhouse
$156 → $89MaintainsStrong BuyGet Alert
07/31/2023Buy Now63.8%Needham
Joseph Stringer
$110 → $60MaintainsBuyGet Alert
07/31/2023Buy Now123.86%HC Wainwright & Co.
Douglas Tsao
 → $82ReiteratesBuy → BuyGet Alert
07/21/2023Buy Now118.4%Citigroup
Yigal Nochomovitz
$106 → $80MaintainsBuyGet Alert
07/21/2023Buy Now123.86%HC Wainwright & Co.
Douglas Tsao
$100 → $82MaintainsBuyGet Alert
07/20/2023Buy Now118.4%Citigroup
Yigal Nochomovitz
$106 → $80MaintainsBuyGet Alert
07/20/2023Buy Now9.2%Wedbush
Laura Chico
$86 → $40MaintainsNeutralGet Alert
07/20/2023Buy Now44.69%Wells Fargo
Derek Archila
$76 → $53MaintainsEqual-WeightGet Alert
07/20/2023Buy Now96.56%JP Morgan
Anupam Rama
$100 → $72MaintainsOverweightGet Alert
07/18/2023Buy Now173%HC Wainwright & Co.
Douglas Tsao
 → $100ReiteratesBuy → BuyGet Alert
06/13/2023Buy Now173%HC Wainwright & Co.
Douglas Tsao
 → $100ReiteratesBuy → BuyGet Alert
05/12/2023Buy Now194.84%Oppenheimer
Justin Kim
$96 → $108MaintainsOutperformGet Alert
05/08/2023Buy Now189.38%Citigroup
Yigal Nochomovitz
$88 → $106MaintainsBuyGet Alert
05/05/2023Buy Now325.88%Raymond James
Steven Seedhouse
$139 → $156MaintainsStrong BuyGet Alert
05/05/2023Buy Now121.13%Credit Suisse
Tiago Fauth
$70 → $81MaintainsNeutralGet Alert
05/05/2023Buy Now107.48%Wells Fargo
Derek Archila
$55 → $76MaintainsEqual-WeightGet Alert
05/05/2023Buy Now173%HC Wainwright & Co.
Douglas Tsao
$87 → $100MaintainsBuyGet Alert
05/05/2023Buy Now200.3%Needham
Joseph Stringer
$80 → $110MaintainsBuyGet Alert
04/20/2023Buy Now137.51%HC Wainwright & Co.
Douglas Tsao
 → $87Reiterates → BuyGet Alert
04/17/2023Buy Now82.91%Wedbush
Laura Chico
$51 → $67MaintainsNeutralGet Alert
04/14/2023Buy Now284.93%Goldman Sachs
Madhu Kumar
$124 → $141MaintainsBuyGet Alert
02/23/2023Buy Now137.51%HC Wainwright & Co.
Douglas Tsao
 → $87Reiterates → BuyGet Alert
02/22/2023Buy Now279.47%Raymond James
Steven Seedhouse
$123 → $139MaintainsStrong BuyGet Alert
02/22/2023Buy Now118.4%Needham
Joseph Stringer
 → $80MaintainsBuyGet Alert
02/21/2023Buy Now104.75%Stifel
Annabel Samimy
$65 → $75MaintainsBuyGet Alert
02/21/2023Buy Now186.65%Baird
Colleen Kusy
$90 → $105MaintainsOutperformGet Alert
02/21/2023Buy Now148.43%Citigroup
Yigal Nochomovitz
$86 → $91MaintainsBuyGet Alert
02/21/2023Buy Now137.51%HC Wainwright & Co.
Douglas Tsao
 → $87Reiterates → BuyGet Alert
02/21/2023Buy Now118.4%Needham
Joseph Stringer
$70 → $80Reiterates → BuyGet Alert
01/03/2023Buy Now58.34%Wells Fargo
Derek Archila
 → $58DowngradeOverweight → Equal-WeightGet Alert
11/15/2022Buy Now115.67%JP Morgan
Anupam Rama
$81 → $79MaintainsOverweightGet Alert
11/10/2022Buy Now9.2%Jefferies
Chris Howerton
$70 → $40DowngradeBuy → HoldGet Alert
11/08/2022Buy Now17.39%Credit Suisse
Tiago Fauth
$45 → $43MaintainsNeutralGet Alert
10/18/2022Buy Now235.79%Raymond James
Steven Seedhouse
$113 → $123MaintainsStrong BuyGet Alert
09/12/2022Buy Now82.91%Wedbush
Laura Chico
$55 → $67MaintainsNeutralGet Alert
09/08/2022Buy Now77.45%Stifel
Annabel Samimy
$60 → $65MaintainsBuyGet Alert
08/18/2022Buy Now112.94%Oppenheimer
Justin Kim
$68 → $78MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Apellis Pharmaceuticals (APLS) stock?

A

The latest price target for Apellis Pharmaceuticals (NASDAQ:APLS) was reported by Goldman Sachs on July 17, 2024. The analyst firm set a price target for $77.00 expecting APLS to rise to within 12 months (a possible 110.21% upside). 66 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Apellis Pharmaceuticals (APLS)?

A

The latest analyst rating for Apellis Pharmaceuticals (NASDAQ:APLS) was provided by Goldman Sachs, and Apellis Pharmaceuticals maintained their buy rating.

Q

When was the last upgrade for Apellis Pharmaceuticals (APLS)?

A

The last upgrade for Apellis Pharmaceuticals Inc happened on February 5, 2024 when Jefferies raised their price target to $80. Jefferies previously had a hold for Apellis Pharmaceuticals Inc.

Q

When was the last downgrade for Apellis Pharmaceuticals (APLS)?

A

The last downgrade for Apellis Pharmaceuticals Inc happened on December 14, 2023 when Wells Fargo changed their price target from $67 to $54 for Apellis Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Apellis Pharmaceuticals (APLS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apellis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apellis Pharmaceuticals was filed on July 17, 2024 so you should expect the next rating to be made available sometime around July 17, 2025.

Q

Is the Analyst Rating Apellis Pharmaceuticals (APLS) correct?

A

While ratings are subjective and will change, the latest Apellis Pharmaceuticals (APLS) rating was a maintained with a price target of $90.00 to $77.00. The current price Apellis Pharmaceuticals (APLS) is trading at is $36.63, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch